Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
November 09, 2020 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020
October 26, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Mavrilimumab reduced time-to-flare and increased sustained remission in Phase 2 giant cell arteritis clinical trial -- Primary and secondary efficacy endpoints achieved statistical significance...